Trading-Stocks.de

Industrial Goods | Diversified Machinery | USA
Danaher Posts Slight Fourth-Quarter Earnings Beat

The industrial and medical device maker beats analysts' adjusted earnings forecasts by a penny.

...

The Washington, D.C-based company said it posted net earnings of $746.8 million, or $1.05 a share, in the fourth quarter, down from $856.6 million, or $1.21 a share, a year earlier.

On an adjusted basis, the company posted per-share earnings of $1.28, above Zacks consensus estimates of $1.27 and the $1.19 it earned a year ago. Revenue increased 5.5% year over year to $5.4 billion vs. $5.09 billion in the year-earlier period.

...

For the full year, Danaher earned $2.7 billion, or $3.74 a share. On an adjusted basis, the company posted net earnings per share of $4.52 vs. $4.03 in 2017.

...

https://www.thestreet.com/investing/earn...yptr=yahoo

Danaher (DHR) Beats on Q2 Earnings and Sales, Ups Guidance

Danaher Corporation DHR reported better-than-expected results in the second quarter of 2019. While earnings beat the Zacks Consensus Estimate by 3.5%, sales surpassed the same by 1.4%.

The company’s adjusted earnings were $1.19 per share in the reported quarter, which outpaced the Zacks Consensus Estimate of $1.15. The reported figure also increased 3.5% over the year-ago quarter’s figure of $1.15 on the back of impressive sales performance and gain from Danaher Business System (“DBS”) initiatives.

Organic Growth & Acquired Assets Drive Sales

In the quarter under review, the company’s net sales were $5,156.6 million, which increased 3.5% from the year-ago quarter’s figure. Organic sales in the quarter grew 5.5% and acquired assets had a positive 1% impact. However, foreign currency translations had a negative impact of 3%.


...

https://finance.yahoo.com/news/danaher-d...02569.html

Danaher (DHR) Beats Q3 Earnings Estimates, Lowers '19 View

Danaher Corporation DHR kept its earnings beat streak alive in the third quarter of 2019, with earnings surpassing estimates by 0.9%. However, sales lagged estimates by roughly 0.1%.

The company’s adjusted earnings were $1.16 per share in the reported quarter, which outpaced the Zacks Consensus Estimate of $1.15. The same also grew 5.5% from the year-ago quarter’s figure of $1.10 on impressive sales performance and gain from Danaher Business System (“DBS”).

Sales Rise on Organic Growth & Buyouts

In the quarter under review, the company’s net sales were $5,037.3 million, which grew 3.8% from the year-ago quarter. Organic sales in the quarter grew 5% and acquired assets had a positive 0.5% impact.


...

https://finance.yahoo.com/news/danaher-d...02996.html

Danaher (DHR) Q4 Earnings and Revenues Top Estimates

Danaher (DHR) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.28 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 1.59%. A quarter ago, it was expected that this industrial and medical device maker would post earnings of $1.15 per share when it actually produced earnings of $1.16, delivering a surprise of 0.87%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Danaher, which belongs to the Zacks Diversified Operations industry, posted revenues of $4.87 billion for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 1.71%. This compares to year-ago revenues of $5.36 billion.


...

https://finance.yahoo.com/news/danaher-d...12729.html

Danaher (DHR) Beats Q1 Earnings Estimates, Provides Bleak View

Danaher Corporation DHR has reported better-than-expected results for the first quarter of 2020, with earnings surpassing estimates by 5%.

The company’s adjusted earnings were $1.05 per share in the reported quarter, which outpaced the Zacks Consensus Estimate of $1.00. The same also grew 6.1% from the year-ago quarter’s figure of 99 cents on sales growth.

Revenue Details

In the quarter under review, the company’s net sales were $4,343.1 million, which grew 2.9% from the year-ago quarter. Organic sales in the quarter grew 4.5%, partially offset by 1.5% adverse impact of foreign-currency translations.


...

https://finance.yahoo.com/news/danaher-d...01533.html

https://seekingalpha.com/article/4378065...ny-sellers

Auch wenn ich den CEO-Wechsel damals bedauert habe, es war, wie es scheint, unschädlich.
Anlagequalität, Trendstärke ..., hier stimmt einfach alles! Auf Jahressicht plus 63%.

(09.10.2020, 16:16)Honnete schrieb: [ -> ]https://seekingalpha.com/article/4378065...ny-sellers

Auch wenn ich den CEO-Wechsel damals bedauert habe, es war, wie es scheint, unschädlich.
Anlagequalität, Trendstärke ..., hier stimmt einfach alles! Auf Jahressicht plus 63%.

So ein Top-wert. Werde ich bei nächstem Crash in 5 Jahren die Aktien kaufen.

Danaher (DHR) Q3 Earnings Beat, Rise Y/Y on Sales Growth

...

The company’s adjusted earnings were $1.72 per share in the reported quarter, which outpaced the Zacks Consensus Estimate of $1.37. The bottom line increased 62.3% from the year-ago quarter’s figure of $1.06 mainly on sales growth and improved operating margin.

Revenue Details
In the quarter under review, the company’s net sales were $5,883.2 million, reflecting year-over-year growth of 34.5%. The results were driven by solid performance in Life Sciences and Diagnostics segments.


...

https://finance.yahoo.com/news/danaher-d...02147.html

Die Aktien von Danaher stiegen am Donnerstag um mehr als 4%, nachdem das Unternehmen bekannt gab, dass es das Privatunternehmen Aldevron für $9,6 Milliarden in bar kaufen wird.
Aldevron stellt qualitativ hochwertige Plasmid-DNA, mRNA und Proteine her und beliefert Biotechnologie- und Pharmakunden in den Bereichen Forschung, klinische und kommerzielle Anwendungen.
Danaher President und Chief Executive Officer Rainer M. Blair sagte, dass die Akquisition die Fähigkeiten des Unternehmens im Bereich der genomischen Medizin erweitern und dazu beitragen wird, mehr lebensrettende Therapien und Impfstoffe schneller auf den Markt zu bringen.
Aldevron wird als eigenständiges Unternehmen und Marke innerhalb des Life-Science-Segments von Danaher operieren.
Danaher erwartet, die Akquisition mit Barmitteln und/oder Erlösen aus der Emission von Commercial Paper zu finanzieren.

https://www.reuters.com/